VRX stock quote – Valeant Pharmaceuticals International, Inc, valeant pharmaceuticals international.#Valeant #pharmaceuticals #international

Posted On Jan 9 2018 by

Valeant Pharmaceuticals International, Inc. Quote & Summary Data Stock Details COMPANY NEWS FUNDAMENTALS Edit Symbol List Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages. Don’t know the stock symbol? Use the Symbol Lookup tool. Alphabetize the sort order of my symbols Symbol Lookup Investing just got easier Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow. “Today’s Low” The lowest sales price the stock has fallen …


Valeant to buy orphan drug developer Aton for $318M #ucb #pharma #inc

Posted On Dec 6 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #china #pharma

Posted On Nov 17 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #usv #pharma

Posted On Aug 31 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #what #is #big #pharma

Posted On Aug 20 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #mankind #pharma

Posted On Aug 11 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


Valeant to buy orphan drug developer Aton for $318M #pharma #resumes

Posted On Aug 4 2017 by

#aton pharma # Valeant to buy orphan drug developer Aton for $318M Valeant Pharmaceuticals is continuing an aggressive buying spree, announcing this morning that it has sealed a deal to buy orphan drugmaker Aton Pharma for $318 million. Aton sells as well as develops therapies for orphan diseases and is expected to reap $80 million to $100 million in revenue for this year. “The acquisition of Aton fits into our long-term strategy to pursue diversified opportunities within the pharmaceutical market and offers us another platform for future growth,” said J. Michael Pearson, chairman and CEO. “With a business that has …


From Valeant to Horizon and Endo, Pharma Gloom Spreads – The Big Number – MoneyBeat #pharma #research #jobs

Posted On Jul 31 2017 by

#endo pharma # From Valeant to Horizon and Endo, Pharma Gloom Spreads The Big Number Mar 21, 2016 8:55 am ET At the start of each week, MoneyBeat publishes a short column in the WSJ print edition highlighting a statistic getting traction in the markets. This week’s “big number“ is $19.67 billion, the combined decline in stock-market value of Valeant Pharmaceuticals International. Mallinckrodt PLC, Horizon Pharma PLC and Endo International PLC last week. Concerns about the fate of Valeant Pharmaceuticals International Inc. has investors not only fleeing Valeant s stock but also shares of companies that bear a resemblance to …


From Valeant to Horizon and Endo, Pharma Gloom Spreads – The Big Number – MoneyBeat #transtech #pharma

Posted On Jun 25 2017 by

#endo pharma # From Valeant to Horizon and Endo, Pharma Gloom Spreads The Big Number Mar 21, 2016 8:55 am ET At the start of each week, MoneyBeat publishes a short column in the WSJ print edition highlighting a statistic getting traction in the markets. This week’s “big number“ is $19.67 billion, the combined decline in stock-market value of Valeant Pharmaceuticals International. Mallinckrodt PLC, Horizon Pharma PLC and Endo International PLC last week. Concerns about the fate of Valeant Pharmaceuticals International Inc. has investors not only fleeing Valeant s stock but also shares of companies that bear a resemblance to …


From Valeant to Horizon and Endo, Pharma Gloom Spreads – The Big Number – MoneyBeat #industrial #pharmacy

Posted On Mar 29 2017 by

#endo pharma # From Valeant to Horizon and Endo, Pharma Gloom Spreads The Big Number Mar 21, 2016 8:55 am ET At the start of each week, MoneyBeat publishes a short column in the WSJ print edition highlighting a statistic getting traction in the markets. This week’s “big number“ is $19.67 billion, the combined decline in stock-market value of Valeant Pharmaceuticals International. Mallinckrodt PLC, Horizon Pharma PLC and Endo International PLC last week. Concerns about the fate of Valeant Pharmaceuticals International Inc. has investors not only fleeing Valeant s stock but also shares of companies that bear a resemblance to …